Discontinuation - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Discontinuation

NASDAQ, RETA

#Discontinuation #Financial Data #kidney #New Employee

RETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

May 29, 2023
05:00

EST

NEW YORK, May 29, 2023 /PRNewswire/ — The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) violated federal securities laws. CURRENT INVESTIGATION DETAILS: On May 10, 2023, Reata issued a press release announcing its financial results for the

No Comments

NASDAQ, RETA

#Class Action Lawsuit #Discontinuation #Financial Data #kidney

REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm

May 26, 2023
21:00

EST

NEW YORK–(BUSINESS WIRE)–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns whether Reata has violated the federal securities laws and/or engaged in other unlawful

No Comments

COST, NASDAQ

#Discontinuation #Negative Financials #Third-Party Article

Costco Q3 results trail estimates on a one-time charge; Goldman remains bullish

May 26, 2023
01:30

EST

Investing — Costco (NASDAQ:COST) reported fiscal third quarter results that missed Wall Street estimates to send its shares almost 1% lower in pre-market Friday. The company attributed weaker-than-expected results to a $0.50 per share one-time charge to discontinue charter shipping activities. Costco reported fiscal Q3 earnings of $2.93 per

No Comments

NASDAQ, RETA

#Class Action Lawsuit #Discontinuation #Financial Data #kidney

RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

May 25, 2023
21:20

EST

NEW YORK, May 25, 2023 /PRNewswire/ — Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA): concerning possible violations of federal securities laws. On May 10, 2023, Reata issued a press release announcing its financial results for

No Comments

APLS, NASDAQ

#Discontinuation #Phase 2 #Trending News

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

May 25, 2023
07:00

EST

WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank score

No Comments

NASDAQ, PTCT

#Discontinuation #Featured #Trending News

PTC Therapeutics Announces Strategic Pipeline Prioritization

May 23, 2023
16:05

EST

– Preclinical and early research gene therapy programs discontinued –– Expected reductions of approximately 15% in residual 2023 OPEX – SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a

No Comments

NASDAQ, WVE

#Discontinuation #New Clinical Trial Data #Phase 1 #Trending News

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

May 23, 2023
07:30

EST

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with clinical outcomes — Wave to discontinue development of WVE-004

No Comments

NASDAQ, RETA

#Class Action Lawsuit #Discontinuation #Financial Data #kidney

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. – RETA

May 19, 2023
14:00

EST

NEW YORK, May 19, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Reata and certain of its officers and/or directors have

No Comments

FUSN, NASDAQ

#Discontinuation #Financial Data

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

May 11, 2023
07:15

EST

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Clinical progress across TAT pipeline continues; first patient dosed in Phase 1 study

No Comments

FRGT, NASDAQ

#Discontinuation #New Partnership #Trending News

Freight Technologies, Inc. Announces Discontinuation of Strategic Alliance with Freight Company from Mexico to Focus on Higher-Margin Opportunities

May 5, 2023
07:00

EST

HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc.. (Nasdaq: FRGT) (“Fr8Tech”), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning offering a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, announces the discontinuation of its alliance

No Comments

< Page1 Page2 Page3 … Page6 >

Trending News

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

05/26/2023

SILVERCORP DECLARES SEMI-ANNUAL DIVIDEND OF US$0.0125 PER SHARE

05/26/2023

Halo Collective Provides Update on Status of Financial Statements

05/26/2023

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2023

US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer

05/26/2023

Most read news

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease

05/25/2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

05/24/2023

Avante Announces Private Placement Closing

05/24/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account